Author(s)

YuXiao Zhang

Affiliation(s)

Department of Statistics and Data Science, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.

Corresponding Author

YuXiao Zhang

ABSTRACT

Objective To explore the impact of COVID-19 on the incidence of thrombosis in Shenzhen, analyze the epidemiological characteristics of thrombotic diseases during the epidemic period, and predict the long-term incidence trend. Methods The data of thrombus patients in the emergency Department of Peking University Shenzhen Hospital from January 2017 to June 2024 were collected. R4.3.1 was used for statistical analysis. Results There were 115 patients with thrombus before the epidemic(January 2017 to December 2019), the male to female ratio was about 0.89:1. During the epidemic period(January 2020-Decenmber 2022), 190 patients with thrombosis were diagnosed, with a male/female ratio of 1.23:1. Since the epidemic(January 2023 to June 2024), 67 patients with thrombosis, the ratio of male to female is about 0.91:1. The number of patients in the 31~60 age group was the largest(51.30%,45.79%,44.78%, respectively). The main type of thrombotic disease was venous thrombosis (90.32%). Conclusion The COVID-19 epidemic significantly increased the incidence of thrombotic diseases, but with the popularization of vaccines and epidemic control, the incidence of thrombotic patients gradually recovered to the pre-epidemic level. 

KEYWORDS

Thrombosis; COVID-19; Epidemiological characteristic; Incidence rate

CITE THIS PAPER

YuXiao Zhang. Analysis of epidemiological characteristics of patients with venous thrombosis in emergency department of a 3A hospital in Shenzhen during Covid-19 epidemic. Journal of Computer Science and Electrical Engineering. 2025, 7(3): 89-94. DOI: https://doi.org/10.61784/jcsee3060.

REFERENCES

[1] F Albani, L Sepe, F Fusina, et al. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 2020, 27: 100562.

[2] Z Zhai, C Li, Y Chen, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: A consensus statement before guidelines. Thromb Haemost, 2020, 120(6): 937–948.

[3] EM Conway, N Mackman, RQ Warren, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol, 2022, 22(10): 639–649.

[4] JA Heit, MD Silverstein, DN Mohr, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost, 2001, 86(1): 452–463.

[5] A Shaik, Q Chen, P Mar, et al. High blood viscosity in acute and recent COVID-19 infections. Clinical Hemorheology and Microcirculation, 2022, 82(2): 149–155.

[6] M Begbie, C Notley, S Tinlin, et al. The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost, 2000, 84(2): 216–222.

[7] BK Manne, F Denorme, EA Middleton, et al. Platelet gene expression and function in patients with COVID-19. Blood, 2020, 136(11): 1317–1329.

[8] JM Connors, JH Levy. COVID-19 and its implications for thrombosis and anticoagulation. Blood, 2020, 135(23): 2033–2040.

[9] JD Mcfadyen, H Stevens, K Peter. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res, 2020, 127(4): 571–587.

[10] AC Walls, YJ Park, MA Tortorici, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020, 181(2): 281–292.

[11] Wang Y. Efficient Adverse Event Forecasting in Clinical Trials via Transformer-Augmented Survival Analysis. Preprints, 2025. DOI:10.20944/preprints202504.2001.v1.